男男性行为者HIV预防:替诺福韦艾拉酚胺联合恩曲他滨暴露前预防与安慰剂的比较
本研究利用DISCOVER和iPrEx试验数据,经逆概率权重标准化后比较替诺福韦艾拉酚胺/恩曲他滨(TAF/FTC)暴露前预防与安慰剂对HIV感染的预防效果。结果显示,TAF/FTC组HIV感染风险较标准化至DISCOVER人群的安慰剂组低5.8个百分点(95%CI -2.0%至-9.6%)或低12.5倍(95%CI 0.02至0.31)。结论认为在96周随访期内TAF/FTC较安慰剂降低了HIV感染风险。
要点
- TAF/FTC暴露前预防较安慰剂降低HIV感染风险5.8个百分点(95%CI -2.0%至-9.6%)。
- TAF/FTC较安慰剂HIV感染风险低12.5倍(95%CI 0.02至0.31)。
- 在96周随访期内观察到TAF/FTC较安慰剂降低HIV感染。
核心结论
- 在96周随访期内,TAF/FTC暴露前预防较安慰剂降低了HIV感染风险。
研究设计与样本
- 本研究利用DISCOVER试验(2016年至2017年,非劣效性试验)和iPrEx试验(2007年至2009年,安慰剂对照试验)的数据比较TAF/FTC与安慰剂。
- 采用逆概率权重将iPrEx参与者标准化至DISCOVER试验的人口学和风险因素分布。
- 通过比较共享的TDF/FTC组HIV感染风险来验证比较的可靠性。
主要发现
- 两试验间人口学和风险因素存在显著差异。
- 标准化后,TDF/FTC组间HIV感染风险差异接近零。
- TAF/FTC组HIV感染风险较标准化至DISCOVER人群的安慰剂组低5.8个百分点(95%CI -2.0%至-9.6%)。
- TAF/FTC组HIV感染风险较标准化至DISCOVER人群的安慰剂组低12.5倍(95%CI 0.02至0.31)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While noninferiority of tenofovir alafenamide and emtricitabine (TAF/FTC) as preexposure prophylaxis (PrEP) for the prevention of human immunodeficiency virus (HIV) has been shown, interest remains in its efficacy relative to placebo. We estimate the efficacy of TAF/FTC PrEP versus placebo for the prevention of HIV infection. METHODS: We used data from the DISCOVER and iPrEx trials to compare TAF/FTC to placebo. DISCOVER was a noninferiority trial conducted from 2016 to 2017. iPrEx was a placebo-controlled trial conducted from 2007 to 2009. Inverse probability weights were used to standardize the iPrEx participants to the distribution of demographics and risk factors in the DISCOVER trial. To check the comparison, we evaluated whether risk of HIV infection in the shared tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) arms was similar. RESULTS: Notable differences in demographics and risk factors occurred between trials. After standardization, the difference in risk of HIV infection between the TDF/FTC arms was near zero. The risk of HIV with TAF/FTC was 5.8 percentage points lower (95% confidence interval [CI], -2.0% to -9.6%) or 12.5-fold lower (95% CI, .02 to .31) than placebo standardized to the DISCOVER population. CONCLUSIONS: There was a reduction in HIV infection with TAF/FTC versus placebo across 96 weeks of follow-up. CLINICAL TRIALS REGISTRATION: NCT02842086 and NCT00458393.
引用
- Zivich PN, Cole SR, Edwards JK, et al. HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo. J Infect Dis. 2024. PMID: 37969014. doi:10.1093/infdis/jiad507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。